Literature DB >> 6816636

Immunogenicity of cyclophosphamide-treated leukaemia cells.

M Kawalec, M Jakóbisiak, T Skórski, J Kawiak.   

Abstract

The median survival time of DBA/2Wf or CD2F1 hybrid mice increased after administration of 10(3) cells of lymphoid leukaemia L 1210 when the recipient mice were injected earlier with L 1210 cells pretreated in vivo with cyclophosphamide. To achieve this effect, at least 10(5) cells treated with cyclophosphamide should be used per mouse. This effect was immunologically specific and could not be induced by L-1 cells treated with cyclophosphamide, and was transferable by means of splenocytes. Such immunoprophylaxis was efficient for at least 100 days. Attempts at immunoprevention by means of the same cells treated with mitomycin C or killed by osmotic shock were unsuccessful.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6816636

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  2 in total

1.  Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.

Authors:  M Kawalec; T Skórski; J Kawiak
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

2.  New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.

Authors:  T Skórski; M Kawalec
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.